Why does iron chelation therapy worsen outcomes in H63D HFE variant carriers despite reducing iron levels?
PARTIALLY ADDRESSED
The study shows deferiprone rescues wild-type cells but exacerbates toxicity in H63D HFE cells, contradicting the assumption that iron reduction is universally protective in neurodegeneration. This paradox has critical implications for personalized Parkinson's treatment strategies.
Gap type: contradiction
Source paper: H63D variant of the homeostatic iron regulator (HFE) gene alters α-synuclein expression, aggregation, and toxicity. (2020, Journal of neurochemistry, PMID:32574378)
Landscape Summary:
Why does iron chelation therapy worsen outcomes in H63D HFE variant carriers despite reducing iron levels? is a 0.89 priority gap in neurodegeneration.
It has 0 linked hypotheses with average composite score 0.000.
Status: partially_addressed.
Key Unanswered Questions
What is the optimal TREM2 modulation strategy across disease stages?
How does DAM activation state affect therapeutic outcomes?
What biomarkers predict response to TREM2-targeted interventions?
Key Researchers
Colonna, Sevlever, et al. (TREM2 biology)
Clinical Trials
Why does iron chelation therapy worsen outcomes in H63D HFE variant carriers despite reducing iron levels? — INVOKE-2 (completed)